000127373 001__ 127373
000127373 005__ 20240228140922.0
000127373 0247_ $$2doi$$a10.1007/s00401-014-1370-3
000127373 0247_ $$2pmid$$apmid:25427834
000127373 0247_ $$2ISSN$$a0001-6322
000127373 0247_ $$2ISSN$$a1432-0533
000127373 0247_ $$2altmetric$$aaltmetric:2932675
000127373 037__ $$aDKFZ-2017-03398
000127373 041__ $$aeng
000127373 082__ $$a610
000127373 1001_ $$0P:(DE-HGF)0$$aReuss, David E$$b0$$eFirst author
000127373 245__ $$aATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an 'integrated' diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
000127373 260__ $$aBerlin$$bSpringer$$c2015
000127373 3367_ $$2DRIVER$$aarticle
000127373 3367_ $$2DataCite$$aOutput Types/Journal article
000127373 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524128329_11666
000127373 3367_ $$2BibTeX$$aARTICLE
000127373 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127373 3367_ $$00$$2EndNote$$aJournal Article
000127373 520__ $$aDiffuse gliomas are represented in the 2007 WHO classification as astrocytomas, oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO grade IV. Molecular data on these tumors have a major impact on prognosis and therapy of the patients. Consequently, the inclusion of molecular parameters in the WHO definition of brain tumors is being planned and has been forwarded as the 'ISN-Haarlem' consensus. We, here, analyze markers of special interest including ATRX, IDH and 1p/19q codeletion in a series of 405 adult patients. Among the WHO 2007 classified tumors were 152 astrocytomas, 61 oligodendrogliomas, 63 oligoastrocytomas and 129 glioblastomas. Following the concepts of the 'ISN-Haarlem', we rediagnosed the series to obtain 'integrated' diagnoses with 155 tumors being astrocytomas, 100 oligodendrogliomas and 150 glioblastomas. In a subset of 100 diffuse gliomas from the NOA-04 trial with long-term follow-up data available, the 'integrated' diagnosis had a significantly greater prognostic power for overall and progression-free survival compared to WHO 2007. Based on the 'integrated' diagnoses, loss of ATRX expression was close to being mutually exclusive to 1p/19q codeletion, with only 2 of 167 ATRX-negative tumors exhibiting 1p/19q codeletion. All but 4 of 141 patients with loss of ATRX expression and diffuse glioma carried either IDH1 or IDH2 mutations. Interestingly, the majority of glioblastoma patients with loss of ATRX expression but no IDH mutations exhibited an H3F3A mutation. Further, all patients with 1p/19 codeletion carried a mutation in IDH1 or IDH2. We present an algorithm based on stepwise analysis with initial immunohistochemistry for ATRX and IDH1-R132H followed by 1p/19q analysis followed by IDH sequencing which reduces the number of molecular analyses and which has a far better association with patient outcome than WHO 2007.
000127373 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000127373 588__ $$aDataset connected to CrossRef, PubMed,
000127373 650_7 $$2NLM Chemicals$$aNuclear Proteins
000127373 650_7 $$0EC 1.1.1.41$$2NLM Chemicals$$aIsocitrate Dehydrogenase
000127373 650_7 $$0EC 1.1.1.42.$$2NLM Chemicals$$aIDH1 protein, human
000127373 650_7 $$0EC 3.6.4.-$$2NLM Chemicals$$aDNA Helicases
000127373 650_7 $$0EC 3.6.4.12$$2NLM Chemicals$$aATRX protein, human
000127373 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b1$$udkfz
000127373 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b2$$udkfz
000127373 7001_ $$0P:(DE-He78)2d0c564eca775a62ff86225f7717af12$$aWiestler, Benedikt Paul Otmar$$b3$$udkfz
000127373 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b4$$udkfz
000127373 7001_ $$0P:(DE-HGF)0$$aKoelsche, Christian$$b5
000127373 7001_ $$0P:(DE-HGF)0$$aSchweizer, Leonille$$b6
000127373 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b7$$udkfz
000127373 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b8$$udkfz
000127373 7001_ $$aHovestadt, Volker$$b9
000127373 7001_ $$0P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aMittelbronn, Michel$$b10$$udkfz
000127373 7001_ $$aSchittenhelm, Jens$$b11
000127373 7001_ $$0P:(DE-He78)c146c0b611b8fb654444ec078766f5ea$$aHerold-Mende, Christel$$b12$$udkfz
000127373 7001_ $$0P:(DE-HGF)0$$aUnterberg, Andreas$$b13
000127373 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b14$$udkfz
000127373 7001_ $$aWeller, Michael$$b15
000127373 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b16$$udkfz
000127373 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b17$$udkfz
000127373 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b18$$eLast author$$udkfz
000127373 773__ $$0PERI:(DE-600)1458410-4$$a10.1007/s00401-014-1370-3$$gVol. 129, no. 1, p. 133 - 146$$n1$$p133 - 146$$tActa neuropathologica$$v129$$x1432-0533$$y2015
000127373 909CO $$ooai:inrepo02.dkfz.de:127373$$pVDB
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d0c564eca775a62ff86225f7717af12$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3494efbbc54460b109fe9eab0595adda$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c146c0b611b8fb654444ec078766f5ea$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000127373 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000127373 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000127373 9141_ $$y2015
000127373 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127373 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL : 2015
000127373 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127373 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127373 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127373 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127373 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127373 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127373 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127373 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127373 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127373 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127373 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127373 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bACTA NEUROPATHOL : 2015
000127373 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000127373 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x1
000127373 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x2
000127373 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x3
000127373 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x4
000127373 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000127373 9201_ $$0I:(DE-He78)L501-20160331$$kL501$$lDKTK Frankfurt$$x6
000127373 9201_ $$0I:(DE-He78)L801-20160331$$kL801$$lDKTK Tübingen$$x7
000127373 980__ $$ajournal
000127373 980__ $$aVDB
000127373 980__ $$aI:(DE-He78)G380-20160331
000127373 980__ $$aI:(DE-He78)G370-20160331
000127373 980__ $$aI:(DE-He78)B062-20160331
000127373 980__ $$aI:(DE-He78)B060-20160331
000127373 980__ $$aI:(DE-He78)G160-20160331
000127373 980__ $$aI:(DE-He78)L101-20160331
000127373 980__ $$aI:(DE-He78)L501-20160331
000127373 980__ $$aI:(DE-He78)L801-20160331
000127373 980__ $$aUNRESTRICTED